Clinical Trial Search

Primary: Maximum Plasma Concentration (Cmax) of Spironolactone and Hydrochlorothiazide Following a Single Oral Dose of Spironolactone/Hydrochlorothiazide 25/25 mg Film Coated…

Primary: QTc Effect of Single Subcutaneous (SC) Injections of Motixafortide (BL-8040) 1.25 mg/kg and 2 mg/kg — -0.6; 1.1; -3.0; -1.1 ms

Primary: Change in Pain Level as Measured by the Visual Analog Scale (VAS). — 1.43; 1.71 score on a scale

Primary: Number of Children Who Select the Target Object as Measured by Gaze Preference. — 47; 44; 71; 56 Participants — p=<0.01

Primary: Overall Summary of Treatment Emergent Adverse Events — 8; 3; 7; 7 Event

Primary: Efficacy Evaluation Through Change in Hemoglobin Levels — 9.56; 9.44; 11.05; 11.11 Hemoglobin levels (g/dL)

Primary: Number of Participants Initiating PrEP — 1; 6 Participants — p=<0.05

Primary: Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST) — 22.2; 9.2; 18.9; 5.4 percentage of participants

Primary: Number (Proportion) of Participants With Adverse Events (AEs) — 7; 5; 4; 4 Participants

Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free

Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants

Primary: Dose Response — -14.23; -15.35; -16.05; -19.22 units on a scale

Primary: Short Treatment of Pneumonia — 47; 87 Participants

Primary: Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object — 0.42; 0.44; 0.49; 0.38 proportion of time — p=<0.01

Primary: The Number of Participants With Reperfusion — 133; 131 Participants — p=0.87